EGFR and non-small cell lung carcinoma: Amplification of EGFR is one of the common mechanisms of acquired resistance following MET TKI therapy [130,133], and METamp has likewise been implicated as a mediator of TKI resistance in EGFR-driven NSCLC [146,147,148].